Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM37GWL)

Drug Name
Benzamidine Drug Info
Synonyms
benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2332
ChEBI ID
CHEBI:41033
CAS Number
CAS 618-39-3
TTD Drug ID
DM37GWL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pro-urokinase DMGKT2L Thrombin deficiency 3B14.Z Approved [4]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [5]
PAI-1 DMY2AEF N. A. N. A. Phase 4 [6]
Amediplase DM4FPM3 Myocardial infarction BA41-BA43 Phase 3 [7]
Upamostat DMFZULI Breast cancer 2C60-2C65 Phase 2 [8]
Saruplase DM1M0PR Thrombosis DB61-GB90 Phase 2 [9]
HTU-PA DMNHE43 Cerebrovascular ischaemia 8B1Z Phase 1/2 [10]
PMID18163548C4 DMHPME3 Myocardial ischemia BA6Z Clinical trial [11]
UK-356202 DMSRK2A Myocardial hypertrophy BC45 Clinical trial [12]
PAI-2 DMRSMW8 N. A. N. A. Discontinued in Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cationic trypsinogen (PRSS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bortezomib DMNO38U Leukemia Approved [14]
MELAGATRAN DM4W8RE N. A. N. A. Phase 3 [15]
Ulinastatin DMIQCFG Premature labour JB00 Phase 3 [16]
Alpha-1 antitrypsin DM5EFXZ Coagulation defect 3B10.0 Phase 2 [17]
Dermolastin DM6WSU2 Atopic dermatitis EA80 Discontinued in Phase 2 [18]
RWJ-56423 DM6BIHE Asthma CA23 Discontinued in Phase 1 [19]
Patamostat DM6HBQJ Hypotension BA20-BA21 Terminated [17]
BMY-44621 DM8R3N0 N. A. N. A. Terminated [20]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [21]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD Discovery agent N.A. Investigative [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Suppressor of tumorigenicity 14 protein (ST14)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US8569313, Inhibitor 18 DMXTCGM N. A. N. A. Patented [23]
US8569313, Inhibitor 14 DMZV6YT N. A. N. A. Patented [23]
US8569313, Inhibitor 19 DMLXG43 N. A. N. A. Patented [23]
US8569313, Inhibitor 15 DMTMG02 N. A. N. A. Patented [23]
PMID23849879C3 DMUW3MT Discovery agent N.A. Investigative [24]
PMID25489658C4d DMWZJT0 Discovery agent N.A. Investigative [25]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine DMFXKN1 Discovery agent N.A. Investigative [26]
Inhibitor 1 [Colombo et al., 2012] DMUQHMP Discovery agent N.A. Investigative [27]
3-tapap DMKSUV9 Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Kallikrein-6 (KLK6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID24900446C5 DMZ5P2K Discovery agent N.A. Investigative [28]
Drug(s) Affected By Epidermal growth factor receptor (EGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [29]
Gefitinib DM15F0X Colon adenocarcinoma Approved [30]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [31]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [32]
Gemcitabine DMSE3I7 Anterior urethra cancer Approved [33]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [34]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [35]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [36]
Selenium DM25CGV N. A. N. A. Approved [37]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Proto-oncogene tyrosine-protein kinase Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [40]
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [43]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [44]
Plicamycin DM7C8YV Hypercalcaemia 5B91.0 Approved [45]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [46]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cationic trypsinogen (PRSS1) TT2WR1T TRY1_HUMAN Inhibitor [2]
Kallikrein-6 (KLK6) TTLPF4X KLK6_HUMAN Inhibitor [2]
Suppressor of tumorigenicity 14 protein (ST14) TTPRO7W ST14_HUMAN Inhibitor [2]
Urokinase-type plasminogen activator (PLAU) TTGY7WI UROK_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Gene/Protein Processing [3]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7566).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases. Bioorg Med Chem. 2004 Jul 1;12(13):3529-42. doi: 10.1016/j.bmc.2004.04.030.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
7 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
8 Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
9 Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
10 Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
11 Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
12 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
13 Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
14 Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
15 Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
16 Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
17 US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
18 Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
19 Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
20 Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
21 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
22 Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
23 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
24 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
25 Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
26 Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418).
28 Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. ACS Med Chem Lett. 2012 Jan 11;3(2):159-64.
29 Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
30 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
31 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
32 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
33 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
34 Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
35 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
36 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
37 Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
38 Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
39 SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
40 Selective activation of Src family kinases and JNK by low levels of chromium(VI). Toxicol Appl Pharmacol. 2003 Aug 1;190(3):214-23. doi: 10.1016/s0041-008x(03)00188-1.
41 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
42 Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
43 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
44 Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
45 Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
46 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
47 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.